Video

Dr. Piccart on Personalized Care for Breast Cancer

Author(s):

Martine J. Piccart, MD, PhD

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses personalized care for patients with breast cancer.

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses personalized care for patients with breast cancer.

According to Piccart, patients are not yet receiving precision medicine for their treatment. It is important for physicians and researchers to collaborate in order to bring this to patients quicker.

The clinical trials need to continue to be centered around the patients in order to see progress in the space, states Piccart.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Related Content
Kari Wisinski, MD, the Endowed Professor of Hematology and Oncology and chief of the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison
November 12th 2024

Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
November 7th 2024

AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Jo Chien, MD
November 4th 2024

Lasofoxifene Suppresses Ki-67 Expression in HR+/HER2– Early-Stage Breast Cancer